New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
19:03 EDTTKMR, MONTekmira receives $1.5M milestone payment from Monsanto
Tekmira Pharmaceuticals (TKMR) announced that it has received a $1.5M milestone payment from Monsanto (MON) following completion of specified program developments. The development milestone is part of the research program under the option agreement Tekmira signed with the agriculture company, which was announced on January 13. The option agreement relates to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. The potential value of the transaction could reach up to $86.2M, following the successful completion of all program milestones.
News For TKMR;MON From The Last 14 Days
Check below for free stories on TKMR;MON the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
08:15 EDTMONMonsanto can execute another reinvention, says Citigroup
Citigroup believes Monsanto is reinventing itself like it did when Roundup went off patent in the late 1990's by using the cash flow from the seeds business to get into new growth areas. Citi thinks management can execute the transition but admits the stock may be range-bound over the near-term. The firm keeps a Buy rating on Monsanto with a $146 price target.
August 20, 2014
14:11 EDTTKMRTekmira lipid nanoparticle targeting Marburg virus highlighted in journal
Subscribe for More Information
12:07 EDTMONMonsanto expects to at least double year ongoing EPS by end of FY19
Subscribe for More Information
12:03 EDTMONMonsanto says on track to deliver upper end of FY14 outlook
Subscribe for More Information
August 18, 2014
10:01 EDTTKMROn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:46 EDTTKMRTekmira initiated with an Outperform at Leerink
Subscribe for More Information
August 13, 2014
17:23 EDTTKMRTekmira breaks regular session low in extended trading
Shares were last down 9.4% to $16.84 in after hours trading. Next support is at $15.87. Resistance is at $17.30, the regular session's low of the day.
17:09 EDTTKMRTekmira down 7% following Q2 results, corporate update
17:04 EDTTKMRTekmira slips in extended session trade, levels to watch
Subscribe for More Information
16:40 EDTTKMRTekmira to resume trading at 5:00pm ET
Subscribe for More Information
16:38 EDTTKMRTekmira sees filing IND, Equiv for TKM-HBV in 2H14
The company said the following: "The single ascending dose portion of the TKM-Ebola Phase I clinical trial has been successfully completed in healthy human volunteers. As per the protocol maximum tolerated dose was established to be 0.3 mg/kg for healthy subjects without steroid premedication. In July, we received notice from the U.S. Food & Drug Administration that our TKM-Ebola program was on clinical hold. Subsequently, the company received written notice from the FDA modifying the clinical hold to a "partial clinical hold," allowing for the potential use of TKM-Ebola in individuals who have a confirmed or suspected Ebola infection. The company remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola. The company expects this matter to be resolved by Q4 2014. Our therapeutic, TKM-Ebola, is currently an unapproved agent and the regulatory framework to support its use in Africa has not yet been established. Given the severity of the situation, we are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols. This includes discussions with government agencies and NGO's, including the WHO, in various countries on the potential use of TKM-Ebola to treat Ebola virus infected individuals. There can be no assurance that an appropriate framework for the use of this product will be found. We will continue to provide updates as necessary when clinical and regulatory pathways become confirmed. Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response, defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity. We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma. We intend to file an Investigational New Drug application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015."
16:34 EDTTKMRTekmira provides operational update
Subscribe for More Information
16:33 EDTTKMRTekmira reports Q2 EPS (28c), consensus (26c)
Reports Q2 revenue $1.8M, consensus $3.69M.
16:25 EDTTKMRTekmira trading halted, pending news
Subscribe for More Information
August 12, 2014
07:15 EDTTKMRWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
06:03 EDTTKMRTekmira implied volatility of 145 at upper end of index mean range
Subscribe for More Information
August 11, 2014
11:04 EDTTKMRActive equity options trading on open
Subscribe for More Information
10:49 EDTTKMRTekmira volatility elevated on wide price movement
Subscribe for More Information
10:14 EDTTKMRTekmira extends its recent rally, levels to watch
Subscribe for More Information
05:54 EDTTKMRStocks with implied volatility movement; COH TKMR
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use